Anteris Technologies (ASX:AVR) heart valve replacement first human study

Anteris Technologies (ASX:AVR) is a structural heart company that has developed a 3D-shaped, single-piece aortic heart valve replacement called DurAVR™ THV, which uses the patented ADAPT® anti-calcification process and innovative tissue-shaping technology.

The First-in-Human Study of the DurAVR™ THV met all safety and performance endpoints, with remarkable hemodynamic function sustained to 12 months.

No mortality, disabling stroke, life-threatening bleeding, or myocardial infarction was reported at 12 months.

These positive results will be further validated in an FDA-approved Early Feasibility Study in early 2023.

DurAVR™ THV has the potential to deliver a game-changing treatment to aortic stenosis patients worldwide.

Following the announcement, shares of Anteris Technologies were up 4.05%.